Herborium Group upgrades its forecasts for 2013 with AcnEase® sales
showing continuous high growth
FORT LEE, N.J., Jan. 29, 2013 /PRNewswire/ -- Herborium Group,
Inc., (OTC Pink: HBRM) www.herborium.com, a Botanical
Therapeutics® Company is happy to upgrade its expected revenues
projections for 2013 discussed in the Press Release of October 15, 2012.
End of 2012 sales results for AcnEase®,
Herborium's one of a kind Botanical Therapeutic® for acne,
and AcnEase® performance in the two first
months of the First Quarter of 2013, show a
consistent growth of over 20% per quarter, therefore
allowing to expect direct sales revenues from the product to
more than double in the present year. This growth should
consequently increase the expected total revenues of the Company to
exceed seven figures. Worldwide investor awareness campaign to
increase investor value resulted from this progress is to start
immediately.
AcnEase® www.acnease.com, targets over 60
million acne sufferers in the US with a specific focus on Adult
Acne (average age of acne sufferer in the USA increased from 21.5 to 26.5 during a last
decade). After a withdrawal of Accutane (Roche
Pharmaceuticals) from the market due to safety concerns, this
dramatically growing and health conscious market was left without
an effective treatment. AcnEase® is an all natural and
effective treatment for adult acne, and is gaining the enthusiastic
reviews from its users. In addition to the US market,
AcnEase® is gaining momentum in Canada, has became a treatment of choice
for male acne in UK, and is steadily increasing its brand
recognition in other EU countries. Over 70 million people in
Europe suffers from acne.
Herborium has also recently received a qualified interest for
distribution of AcnEase® in South-East Asia.
"We are very pleased with the AcnEase® sales results of
in 2012, and with its momentum in 2013. We expect this
sales progress to continue aggressively. In addition to a domestic
growth, an opportunity to enter new markets and new
distribution arrangements abroad should become a lynchpin of
Herborium's profitability in 2013," commented Dr.
Agnes P. Olszewski, CEO and
Chairwomen of Herborium Group.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company,
focuses on developing, licensing, and marketing proprietary,
botanical based medicinal products to consumers and healthcare
professionals. The Company uses clinical validation to
establish and maintain a differential advantage. The company
sells its products in the US and Europe. For more information, please visit
www.herborium.com and www.acnease.com
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time, and we disclaim any obligation to update or
alter forward-looking statements as the result of new information
or future events. The Company urges investors to review the risks
and uncertainties contained within its filings with the OTC Markets
and/or Securities and Exchange Commission.
For more information please inquire:
Investorsrelations@herborium.com
SOURCE Herborium Group, Inc.